poisar

Stocks · News reference

CareDx shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $65 to $80.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CDNA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. CareDx Announces New KOAR Data at ASN Kidney Week 2026

    CareDx released new data from the KOAR study demonstrating that elevated AlloSure Kidney levels are associated with a nearly 3-fold higher risk of adverse graft outcomes in patients with borderline rejection or T-cell mediated rejection (TCMR).

    CDNA